NCT03139032

Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 1 (actual)
• Sponsor: Arena Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this phase 2a, proof of concept, open-label clinical study is to evaluate the efficacy and safety of etrasimod (APD334) in inflammatory bowel disease patients with active skin extra-intestinal manifestations.

Conditions

• Inflammatory Bowel Diseases
• Skin Extra-intestinal Manifestations

Interventions

Type	Name	Description
DRUG	APD334	APD334 active treatment for 12 weeks.

Timeline

• Start date: 2017-07-17
• Primary completion: 2017-12-06
• Completion: 2017-12-06
• First posted: 2017-05-03
• Last updated: 2020-12-31
• Results posted: 2020-12-31

Locations

3 sites across 3 countries: Belgium, Germany, Serbia

Regulatory

• FDA-regulated drug study